Clinical Study Of Tongqiao Huoxue Decoction In Treating Mild Cognitive Impairment Of Cerebral Small Vessel Disease

Objective: Observe the clinical effect of Tongqiao Huoxue Decoction in treating mild cognitive impairment of cerebral small vessel disease.Method: 66 patients with mild cognitive impairment of cerebral small vessel disease,were observed and randomly divided into two groups of 33 patients with a random number table.All of them were given conventional basic treatment,and those with other diseases were given corresponding treatment.The treatment group was given Tongqiaohuoxue Decoction;the control group was given 200 mg citicoline sodium capsules orally once,three times a day.Observation for 12 weeks.The Montreal Cognitive Assessment Scale(Mo CA),Mini-mental State Examination(MMSE),Activities of Daily Living(ADL)and TCM symptom curative effect score,were performed at the beginning of the research and at the 4th,8th,and 12 th week.And judge the causal relationship between the adverse reaction and the drug,Result: 1.At the beginning of the experiment,the general data of the two groups of patients,including age,gender,and scores on each scale,were not significantly different(P>0.05),and they were comparable.2.Comparison between groups: the treatment group and the control group have no significant differences in TCM syndrome scores,MMSE,and ADL at the 4th and 8th week of the test(P>0.05),but there are differences at the 12 th week(P<0.05));There was no significant difference in the Mo CA score at the 4th week of the test(P>0.05),but there was a difference at the 8th and 12 th weeks(P<0.05).3.Intra-group comparison: There was no significant difference in TCM syndrome scores,MMSE,ADL,and Mo CA scores between the 4th week of the treatment group and the beginning of the trial(P>0.05),and the 8th and12 th weeks were significant compared with the beginning of the trial.Difference(P<0.05);there is no significant difference in the scores of TCM syndromes,MMSE,and ADL between the 4th and 8th weeks of the control group and the beginning of the test(P>0.05),and it is significant when compared with the beginning of the test at the 12 th week The difference(P<0.05),the Mo CA score was not significantly different between the 4th week and the beginning of the trial(P>0.05),and there was a significant difference between the 8th and 12 th weeks and the beginning of the trial(P<0.05);and The treatment cycle was prolonged,and the scores of TCM syndromes,MMSE,ADL,and Mo CA were improved in the two groups,and the improvement in the treatment group was more significant than that in the control group.4.Judging the clinical efficacy by Mo CA scale and TCM syndrome score,the treatment group is better than the control group(P<0.05).5.The three major routines,liver and kidney function,electrocardiogram and other indicators of the two groups of patients were not significantly changed compared to before enrollment,but the treatment group had fewer adverse reactions than the control group,and the safety was higher.Conclussion : Tongqiao Huoxue Decoction can significantly improve the cognitive function of patients with mild cognitive impairment of cerebral small vessel disease related to blood stasis and collaterals syndrome,and can significantly improve the patient’s TCM syndrome score,Mo CA score,MMSE score,and ADL score,and improve patient’s ability of daily living.Tongqiao Huoxue Decoction is a safe and effective method for treating mild cognitive dysfunction related to cerebral small vessel disease,and it is worthy of clinical promotion.